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Sulindac is chemopreventive and has utility in patients with familial adenomatous polyposis; however,
side effects preclude its long-term use. NOSH-sulindac (AVT-18A) releases nitric oxide and hydrogen
sulﬁde, was designed to be a safer alternative. Here we compare the gastrointestinal safety, anti-in-
ﬂammatory, analgesic, anti-pyretic, anti-platelet, and anti-cancer properties of sulindac and NOSH-su-
lindac administered orally to rats at equimolar doses. Gastrointestinal safety: 6 h post-administration,
number/size of hemorrhagic lesions in stomachs were counted. Tissue samples were frozen for PGE2,
SOD, and MDA determination. Anti-inﬂammatory: 1 h after drug administration, the volume of carra-
geenan-induced rat paw edemas was measured for 5 h. Anti-pyretic: fever was induced by LPS (ip) an
hour before administration of the test drugs, core body temperature was measured hourly for 5 h. An-
algesic: time-dependent analgesic effects were evaluated by carrageenan-induced hyperalgesia. Anti-
platelet: anti-aggregatory effects were studied on collagen-induced platelet aggregation of human pla-
telet-rich plasma. Anti-cancer:We examined the effects of NOSH-sulindac on the growth properties of 12
human cancer cell lines of six different tissue origins. Both agents reduced PGE2 levels in stomach tissue;
however, NOSH-sulindac did not cause any stomach ulcers, whereas sulindac caused signiﬁcant bleeding.
Lipid peroxidation induced by sulindac was higher than that from NOSH-sulindac. SOD activity was
signiﬁcantly lowered by sulindac but increased by NOSH-sulindac. Both agents showed similar anti-
inﬂammatory, analgesic, anti-pyretic, and anti-platelet activities. Sulindac increased plasma TNFα
whereas this rise was lower in the NOSH-sulindac-treated animals. NOSH-sulindac inhibited the growth
of all cancer cell lines studied, with potencies of 1000- to 9000-fold greater than that of sulindac. NOSH-
sulindac inhibited cell proliferation, induced apoptosis, and caused G2/M cell cycle block. These results
demonstrate that NOSH-sulindac is gastrointestinal safe, and maintains the anti-inﬂammatory, analgesic,
antipyretic, and antiplatelet properties of its parent compound sulinsac, with anti-growth activity against
a wide variety of human cancer cells.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The use of anti-inﬂammatory drugs (NSAIDs) in cancerB.V. This is an open access article u
ﬁde; NOSH, nitric oxide-hy-
ry drugs; SUL, sulindac; LPS,
londialdehyde; SOD, Super-
ogy, Pharmacology and Neu-
ol, 138th Street and Convent
212 650 7692.prevention is based on the recognition that inﬂammation is cen-
tral to the carcinogenesis process [1]. There is considerable body of
evidence suggesting that the long-term use of NSAIDs is associated
with a signiﬁcant reduction in many forms of cancers including,
colon [2–5], breast [6–8], pancreas [9], bladder [10,11], head and
neck [12], esophageal [13], ovarian [14,15], prostate [16], hepato-
cellular [17], and skin [18–20]. Of these, cellular and molecular
mechanisms of colorectal cancer (CRC), which in many ways re-
present the prototypical case for cancer prevention, have been
studied most extensively. From all accumulated data, what has
become abundantly clear is that although NSAIDs are chemopre-
ventive, they reduce the risk of, and mortality from, CRC by aboutnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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niﬁcant side effects, mainly gastrointestinal, cardiovascular, and
renal which obviously limits their use [1].
Familial adenomatous polyposis (FAP) is an autosomal domi-
nant disease caused by a mutation in the adenomatous polyposis
coli (APC) gene [22] which is characterized by hundreds of color-
ectal adenomatous polyps that eventually progress to CRC. Almost
all FAP patients will develop CRC if they are not identiﬁed and
treated at an early stage. Generally, management of patients with
FAP is with a total colectomy [23]. Therefore, chemoprevention in
this setting is of paramount importance. Sulindac (SUL) belongs to
the indene class of NSAIDs [24] that has extensively been studied
and utilized as a chemopreventive agents in patients with FAP
[25–28]. However, a limiting factor in the long term use of SUL is
its toxicity, that can affect up to 20% of patients [24]. In our efforts
on improving the safety proﬁle of SUL, we developed NOSH-su-
lindac (NOSH-SUL), a hybrid molecule capable of releasing nitric
oxide (NO) and hydrogen sulﬁde (H2S), two gasotransmitters of
physiological signiﬁcance [29]. Our rational for developing NOSH-
SUL was based on the observations that NO [30] and H2S [31] have
some of the same properties as prostaglandins within the gastric
mucosa, thus modulating some components of the mucosal de-
fense systems. In the present study, we carried out a head-to-head
comparison of the gastrointestinal safety, anti-inﬂammatory, an-
algesic, anti-pyretic, and anti-platelet, properties of SUL with those
of NOSH-SUL. We also evaluated the effects of SUL and NOSH-SUL
in 12 different cancer cell lines of 6 different tissue origins and on
cell kinetics using a human colon cancer cell line.2. Materials and methods
2.1. Chemicals
NOSH-SUL (AVT-18A), (Z)-4-(3-thioxo-3H-1,2-dithiol-5-yl)
phenyl 5-(2-(5-ﬂuoro-2-methyl-1-(4-(methylsulﬁnyl) benzyli-
dene)-1H-inden-3-yl) acetoxy)-2-((4-(nitrooxy) butanoyl)oxy)
benzoate was synthesized as described previously [29] and was a
gift from Avicenna Pharmaceuticals Inc, (New York, NY). The
structural components of the NOSH-SUL are shown in Fig. 1. Li-
popolysaccharide (LPS) from Escherichia coli, SUL, and carrageenan
were purchased from Sigma (St. Louis, MO, USA). Kits used for
determination of PGE2, lipid peroxidation, and superoxide dis-
mutase, were from Cayman Chemical (Ann Arbor, MI).
2.2. Experimental groups and treatments
In all the protocols described below, we used at least 5 male
Wistar rats per group that weighed 180–200 g. The rats were ob-
tained from Charles River Laboratories International (Wilmington,Fig. 1. Structural components of NOSH-sulindac. The parent compound sulindac is
shown in the shaded box. The parts of the molecule that releases NO and H2S are
shown in the dotted ellipses.MA) and were fed standard laboratory chow and water. All ex-
perimental procedures were approved by our institutional animal
research committees and were performed in accordance with
nationally approved guidelines for the treatment of laboratory
animals.
2.3. Determination of ulcer index
Rats were fasted for 48 h with free access to drinking water.
SUL and NOSH-SUL at equimolar concentrations, 200 mg/kg and
467 mg/kg respectively, were administered orally by gavage sus-
pended in 1% carboxymethylcellulose (CMC) solution. Six hours
post-administration, animals were euthanized in a CO2 chamber;
stomachs were then removed immediately, cut along the greatest
curvature, and rinsed with ice-cold distilled water. The ulcer index
(UI) was determined as described by Best et al. [32]. Brieﬂy, the
number and the length of ulcers observed in each stomach were
determined using a magnifying lens. Using the following scoring
module, the severity of each gastric lesion was measured along its
greatest length with 1 mm¼rating of 1, 1–2 mm¼rating of 2, and
42 mm¼rating according to the measured length in mm. The
“ulcer index” (UI) was then calculated by adding the total number
of lengths (L, mm) in each stomach and then dividing the total by
the total number of rats in each group (N¼5): UI¼
(L1þL2þL3þL4þL5)/5.
The excised tissues from each of the stomachs were processed
for measurement of Prostaglandin E2 (PGE2), malondialdehyde
(MDA) and Superoxide dismutase (SOD) activity. Blood samples
from each of the rats were taken by cardiac puncture into heparin-
containing vials and used for determination of plasma TNFα.
2.4. Measurement of PGE2 levels
One gram of tissue from each stomach was placed in a test tube
containing 5 mL of 0.1 M phosphate buffer (pH7.4), 1 mM EDTA,
and 10 μM indomethacin. After homogenization, the homogenate
was centrifuged at 10,000 g for 10 min at 4 °C. PGE2 content in
the supernatant was determined in duplicate by an enzyme im-
munoassay kit following the protocol described by the manu-
facturer (Cayman Chemical, Ann Arbor, MI). Brieﬂy, standard
(50 mL) or homogenate (50 mL), enzymatic tracer (50 mL) and spe-
ciﬁc antiserum (50 mL) were mixed. After overnight incubation at
4 °C, the plates were washed with wash buffer and Ellman reagent
(200 μL) was added into each well. The absorbance at 412 nm was
measured after 1 h incubation at room temperature. Results are
expressed as pg of PGE2 per mg of protein. Proteins were de-
termined by Biorad assay.
2.5. Determination of Malondialdehyde (MDA) levels as index of
lipid peroxidation
Snap frozen stomach tissue (25 mg) was sonicated for 15 s at
40 V over ice with 250 μL of radioimmunoprecipitation (RIPA)
buffer (25 mM TrisHCl pH 7.6, 150 mM NaCl, 1% NP-40, 1% sodium
deoxycholate, 0.1% SDS) with PMSF (phenylmethylsulphonyl
ﬂuoride). Homogenates were centrifuged for 10 min at 200 g at
4 °C. Thiobarbituric acid reactant substances (TBARS) was mea-
sured in the supernatant using a kit from Cayman Chemical (Ann
Arbor, MI) as described by the manufacturer. Brieﬂy, reaction of
malondialdehyde (MDA) with thiobarbituric acid (TBA) at high
temperature (90–100 °C) in acidic conditions produced an adduct
with a chromophore which absorbed visible light at 530–540 nm.
Results are expressed as picomoles of malondialdehyde per gram
protein.
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SOD activity in the gastric mucosa was assayed using a colori-
metric kit from Cayman Chemical, (Ann Arbor, MI). Mucosal tissue
(1 g) was homogenized with 5 mL of 20 mM HEPES buffer (pH 7.2)
containing 1 mM EGTA and 300 mM of sucrose solution. Homo-
genates were centrifuged at 200 g for 10 min at 4 °C. SOD ac-
tivity of the supernatants were measured spectrophotometrically
at 460 nm. As indicated in Cayman's SOD assay kit, “this procedure
utilizes a tetazolium salt for detection of superoxide radicals
generated by xanthine oxidase and hypoxanthine”. SOD activity is
expressed as the amount of the SOD standard showing activity
equivalent to the determined activity. The results are expressed as
units (U) of SOD activity/mg protein. One unit of SOD is deﬁned as
the amount of enzyme needed to exhibit 50% dismutaion of the
superoxide radical.
2.7. Determination of plasma TNF-α
Plasma TNF-α was measured using an enzyme immunoassay
kit from R&D systems (Minneapolis, MN) following the protocol
described by the manufacturer. Brieﬂy, each sample (50 μL) was
incubated with antibodies speciﬁc for rat TNF-α and washed three
times with assay buffer. An enzyme-linked polyclonal antibody
speciﬁc for rat TNF-α conjugated to horseradish peroxidase was
then added. Following washing of unbound antibody-enzyme re-
agent, substrate solution containing tetramethylbenzidine (TMB),
plus hydrogen peroxide was then added. The enzyme reaction
produced a blue product (oxidized TMB) that turned yellow when
dilute hydrochloride acid (stop solution) was added. Color in-
tensity was determined at 450 nm using a standard ELISA plate
reader. Results are expressed as pg/mL.
2.8. Anti-pyretic activity
Fever was induced in animals as described previously [33].
Brieﬂy, LPS (50 μg/kg, Sigma, St. Louis, MO, USA) was administered
intra-peritoneally to the animals an hour before the administra-
tion of SUL or NOSH-SUL at equimolar doses, 200 mg/kg and
467 mg/kg respectively, given orally by gavage suspended in 1%
CMC. Rectal temperature was measured by inserting a lubricated
thermistor probe (external diameter: 3 mm) 2.8 cm into the rec-
tum of the animal. The probe was linked to a digital reader, which
displayed the temperature at the tip of the probe (70.1 °C). The
values displayed were manually recorded. Rectal temperatures
were taken every hour for 5 h.
2.9. Anti-inﬂammatory activity
Carrageenan (1%, 100 μL, suspended in sterile saline solution)
was subcutaneously injected into the plantar surface of the right
hind paw in rat following the protocol described by Winter et al.
[34]. Paw volume was measured using a water displacement ple-
thysmometer (Model 520, IITC/Life Sciences Instruments, Wood-
land Hills, CA) before carrageenan injection and thereafter at 1 h
intervals for 5 h. The paw volume measured just prior to carra-
geenan injection was used as the control volume. Data are ex-
pressed as the change in paw volume (mL) at each time point. At
the end of the experiment, rats were euthanized by asphyxiation
in a CO2 chamber. After cutting each hind paw at the level of the
calcaneus bone, exudates (oedema ﬂuid) were collected and pro-
cessed for measurement of PGE2, as described in Section 2.4.
2.10. Analgesic activity
Hindpaw inﬂammation was produced by intraplantar injectionof carrageenan (100 μL of 1% carrageenan in sterile saline solution)
into the right paw. SUL or NOSH-SUL at equimolar concentrations,
200 mg/kg and 467 mg/kg respectively, were administered orally
by gavage suspended in 0.5% CMC 1 h after carrageenan injection,
and the mechanical nociceptive threshold was determined 30 min
after this and thereafter every 1 h for up to 5 h. The paw hyper-
algesia was measured with an electronic pressure-meter. Each
hindpaw was positioned in turn under a conical probe surface (tip
radius approximately 1 mm) and gradually increasing pressure
applied to the hindpaw surface until the animal vocalized at which
point the measurement was terminated. Mechanical nociceptive
threshold for both the injected and contralateral (i.e. non-injected)
hindpaw were determined. The animals were tested before and
after treatments and the results are expressed by the delta reac-
tion force (g).
2.11. Inhibition of human platelet aggregation in vitro
Anti-aggregatory effects of SUL and NOSH-SUL were evaluated
on collagen-induced platelet aggregation of human platelet-rich
plasma (PRP). The collagen-induced aggregation occurs through a
pathway dependent upon the arachidonic acid cascade [35]. Ve-
nous blood samples from healthy volunteers who had not taken
any drugs for at least 2 weeks were used to prepare PRP by cen-
trifugation of citrated blood at 200g for 20 min. Aliquots (500 μL)
of PRP were added into aggregometer cuvettes, and aggregation
was recorded as increased light transmission under continuous
stirring (1000 rpm) at 37 °C for 10 min after the addition of the
stimulus. Collagen at submaximal concentrations (1.0 μg/mL) was
used as the platelet activator. Sulindac and NOSH-SUL at various
concentrations were preincubated with PRP 10 min before the
addition of collagen. Vehicle alone (0.5% DMSO) added to PRP did
not affect platelet function in control samples. The anti-ag-
gregatory activity of the two compounds was determined as per-
cent inhibition of platelet aggregation compared to control sam-
ples. IC50 values were calculated by nonlinear regression analysis.
2.12. Measurement of COX enzyme activity
NOSH-SUL was compared to SUL for its ability to inhibit COX-1
and COX-2 enzyme activities in vitro as described previously [36]
using a colorimetric COX (ovine, o-COX) inhibitor screening kit
from Cayman Chemicals (Ann Arbor, MI).
2.13. Cell culture and MTT assay
Human colon adenocarcinoma (HT-29, SW-480 and HCT-15),
human breast cancer (MDA-MB 231, SK-BR-3 and MCF-7), human
pancreatic cancer (MIA PaCa-2 and BxPC-3), human lung cancer
(A549 and H383), human prostate cancer (LNCAP), and human
leukemia (Jurkat T) cells were obtained from American Type Tissue
Collection (Manassas, VA). All cells lines were grown as mono-
layers except for the Jurkat T cells which was grown as suspension
culture. The pancreatic and breast cancer cells were grown in
Dulbecco's modiﬁed Eagle's medium, the prostate, Jurkat, SW-480
and HCT-15 colon cells were grown in RPMI 1640 medium, the
lung cells were grown in F-12 and the colon HT-29 cells were
grown in McCoy 5A. All media were supplemented with 10% fetal
calf serum (Invitrogen, Carlsbad, CA) penicillin (50 U/mL), and
streptomycin (50 mg/mL) (Invitrogen, Carlsbad, CA). Cells were
incubated at 37 °C in 5% CO2 and 90% relative humidity. Single cell
suspensions were obtained by trypsinization (0.05% trypsin/EDTA),
and cells were counted using a hemacytometer. The ﬁnal DMSO
concentration was adjusted in all media to 1%. Viability was de-
termined by the trypan blue dye exclusion method.
Cell growth inhibitory effect of SUL and NOSH-SUL was
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IN). Cancer cells were plated in 96-well plates at a density of
25,000 cells/well. The cells were incubated for 24 h with different
concentrations of SUL and NOSH-SUL after which 10 mL of MTT dye
(3-[4,5–dimethylthiazol–2–yl]-2,5-diphenyl tetrazolium bromide,
5 mg/mL in phosphate buffered saline), was added to each well,
and the plates were incubated for 2 h at 37 °C. Then, the media
was aspirated, and 100 μL of the solubilization solution (10% SDS
in 0.01 M HCl) was added to each well. The absorbance was
measured on a spectrophotometric plate reader at a wavelength of
570 nm.
2.14. Cell proliferation
PCNA antigen expression was determined using an ELISA Kit
(Calbiochem, La Jolla, CA), following the manufacturers protocol.
HT-29 cells (1106 cells/mL) were incubated with serum-free
media for 24 h to remove the effect of endogenous growth factors;
they were then treated for 24 h with various concentrations of
NOSH-SUL or vehicle as previously reported [37].
2.15. Cell cycle analysis
Cell cycle phase distributions of control and treated HT-29 cells
were obtained using a Coulter Proﬁle XL equipped with a single
argon ion laser. For each subset, 410,000 events were analyzed.
All parameters were collected in list mode ﬁles. Data were ana-
lyzed on a Coulter XL Elite Work station using the Software pro-
grams MultigraphTM and MulticycleTM. HT-29 Cells (0.5106)
treated with various concentrations of NOSH-SUL or vehicle were
ﬁxed in 100% methanol for 10 min at 20 °C, pelleted
(5000 rpm10 min at 4 °C), resuspended and incubated in PBS
containing 1% FBS/0.5% NP-40 on ice for 5 min. Cells were washed
again in 500 mL of PBS/1% FBS containing 40 mg/mL propidium
iodide (used to stain for DNA) and 200 mg/mL RNase type IIA, and
analyzed within 30 min by ﬂow cytometry. The percentage of cells
in G0/G1, G2/M, and S phases was determined form DNA content
histograms as reported previously [37].
2.16. Assay for apoptosis
HT-29 cells (0.5106 cells/mL) were treated for 24 h with
various concentrations of NOSH-SUL or vehicle. Cells were washed
with and resuspended in 1Binding Buffer (Annexin V bindingFig. 2. NOSH-sulindac is gastrointestinal safe. SUL and NOSH-SUL were administered ora
SUL, respectively) and effects on the stomach were evaluated as indicated in Section 2.
treated rat showing ulceration and bleeding; Panel C, stomach of a NOSH-SUL-treate
UI¼135715 mm (†Po0.01 compared to vehicle), NOSH-SUL was gastric damage-spa
representative from 5 rats in each group. Results in Panel D are mean7SEM of 5 rats ibuffer, 0.1 M HEPES/NaOH (pH 7.4), 1.4 M NaCl, 25 mM CaCl2; BD
BioSciences Pharmingen, San Diego, CA). Then 5 mL of Annexin
V-FITC (ﬁnal concentration 0.5 mg/mL) was added followed by
propidium iodide as a counterstain (ﬁnal concentration
20 mg/mL). The cells were then incubated at room temperature for
15 min in the dark. Finally, the cells were transferred to FACS tubes
for analysis. Percentage of apoptotic cells were obtained using a
Becton Dickinson LSR II equipped with a single argon ion laser. For
each subset, about 10,000 events were analyzed. All parameters
were collected in list mode ﬁles. Data was analyzed by Flow Jo
software as reported previously [37].
2.17. Statistical analysis
In vivo treatment groups and number of animals in each group
are indicated in the ﬁgure legend. In vitro data are presented as
mean7SEM for at least three different sets of plates done in tri-
plicate. Comparisons between groups were performed using a
one-way analysis of variance followed by the Student-t test.
Po0.05 was regarded as statistically signiﬁcant.3. Results and discussion
3.1. NOSH-SUL is gastrointestinal safe
The rats receiving the vehicle (0.5% CMC solution) had a normal
glandular region on the surface of their stomach, and no ulcerative
damage (Fig. 2A and D). For these rats, the gastric damage score
(also described in the literature as “ulcer index”, or UI), was zero
(UI¼0). Administration of SUL (200 mg/kg) resulted in extensive
mucosal injury, UI¼130 (Fig. 2B and D). NOSH-SUL (476 mg/kg)
did not produce signiﬁcant ulcerative damage (Fig. 2C and D),
UI¼10 compared to SUL at equimolar doses, which represents a
remarkable reduction (Po0.01) in gastrointestinal toxicity. Thus,
this modiﬁed sulindac which has been shown to releases NO and
H2S [29] appears to be gastrointestinal safe. As alluded to in the
introduction, SUL has extensively been utilized as a chemopre-
ventive agent in patients with FAP [25–28]. However, a limiting
factor in its long-term use is its GI toxicity. Based on the data
presented here, NOSH-SUL would be an ideal drug candidate for
development in such a setting.lly at equimolar doses (0.56 mmol/kg; 200 mg/kg and 467 mg/kg for SUL and NOSH-
3. Panel A, shows the stomach of a vehicle-treated rat; Panel B, stomach of a SUL-
d rat which is essentially devoid of ulcers. Panel D, gastric damage due to SUL,
ring, UI¼1071 mm (*Po0.01 compared to SUL). Photographs in Panels A–C are
n each group.
Fig. 3. Effects of sulindac and NOSH-sulindac on gastric PGE2 levels, lipid peroxidation (MDA) and superoxide dismutase (SOD). At the end of the gastrointestinal safety
evaluations as described in Section 2.3, tissues from the excised stomachs of each rat was snap frozen in liquid nitrogen and processed as described in Sections 2.4–2.6. SUL
and NOSH-SUL caused a signiﬁcant reduction in gastric mucosal PGE2 levels (panel A). Results are mean7SEM of 5 rats in each group, *Po0.05 vs vehicle group, †Po0.05 vs
NOSH-SUL group. SUL caused an almost 9-fold increase in MDA levels, for NOSH-SUL-treated rats, MDA levels were about 2-fold higher (panel B). Results are mean7SEM for
5 rats in each group, †Po0.01 vs vehicle group, §Po0.05 vs SUL group. SUL caused a signiﬁcant reduction in SOD activity, whereas NOSH-SUL did not have an effect (panel C).
Results are mean7SEM of 5 rats in each group, †Po0.05 vs vehicle group, †Po0.01 vs SUL group.
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We investigated the effect of SUL and NOSH-SUL on pros-
taglandin E2 (PGE2) content in gastric mucosa (Fig. 3A). Rats
treated with SUL (200 mg/kg) produced about 88% less PGE2 than
rats in the control group. NOSH-SUL (467 mg/kg) also reduced
PGE2 levels but not to the same extent as SUL, the reduction being
around 75% (Fig. 3A). Prostaglandins are the main product of cy-
clooxygenase-mediated arachidonic acid metabolism in gastric
mucosa, therefore, comparison of PGE2 content between control
and drug-treated groups showed a clear and signiﬁcant COX in-
hibition by both SUL and NOSH-SUL. In order to conﬁrm that in-
deed COX enzyme activity was being inhibited, we evaluated the
effects of these two compounds on ovine COX-1 and COX-2 en-
zymatic activity at their respective IC50s for cell growth inhibition,
in HT-29 colon cancer cells (see Section 3.9). As shown in Table 1,
NOSH-SUL at a concentration of 90 nM inhibited COX-1 enzymatic
activity of more than that of COX-2, the respective values being
4471% and 1471%. SUL at 800 mM inhibited COX-1 by 8272%
and COX-2 by 6871%. Therefore, SUL at its IC50s for cell growth
inhibition inhibits both COX-1 and COX-2 more than NOSH-SUL at
IC50s for cell growth inhibition. Since NOSH-SUL is signiﬁcantlyTable 1
NOSH-SUL inhibits cyclooxygenase enzyme activity.
Treatment COX-1 % Inhibition COX-2 % Inhibition
SUL, 800 mM 8272 6871
NOSH-SUL, 90 nM 4471 1471
Indomethacin, 1 mM 7472 6871
Pure ovine COX enzymes were treated with SUL or NOSH-SUL at their respective
IC50s for cell growth inhibition in HT-29 colon cancer cell line for 15 min at 4 °C
after which o-COX-1 and o-COX-2 enzyme activity were determined. Results are
mean7range of two independent studies performed in duplicate.more potent than SUL, this strongly suggests that targets other
than COX must be contributing to its mode of action. We also
measured the degree of COX-1 and COX-2 inhibition by in-
domethacin (1 mM) a nonselective COX inhibitor [38] as a re-
ference compound in order to ensure that there were no anoma-
lies with our assay system. Indomethacin inhibited COX-1 and
COX-2 by 7472% and 6871%, respectively (Table 1).3.3. Effect of NOSH-SUL on lipid peroxidation and superoxide dis-
mutase activity
Measuring the concentration of MDA in intact mucosa 6 h post-
administration of SUL and NOSH-SUL at 200 mg/kg and 476 mg/kg
respectively was used to assess oxidative stress in gastric tissue.
MDA levels were 871 nmol/mg protein in the vehicle treated rats
(Fig. 3B), this was increased to 6872 nmol/mg protein in the SUL
treated rats but was signiﬁcantly less in the NOSH-SUL treated
animals, 3271 nmol/mg protein, (Fig. 3B). Samples from the same
gastric tissues were used to measure SOD activity. In the intact
mucosa (control group) SOD activity was 3.270.3 U/mg protein.
Following administration of SUL a signiﬁcant decrease in SOD ac-
tivity was observed (0.970.1 U/ mg protein, †Po0.05 compared to
vehicle). However, in the NOSH-SUL treated rats, SOD activity was
signiﬁcantly increased to 4.470.3 U/mg protein (nPo0.01 com-
pared to SUL, Fig. 3C). SOD is an antioxidative marker. Its activity
was signiﬁcantly lowered in the SUL-treated animals, this may
explain the high levels of MDA and ulcerations observed in the
stomachs. SOD activity was signiﬁcantly higher in the NOSH-SUL-
treated animals, which correlated with lower MDA levels and es-
sentially no ulcerations to the stomachs. Thus, some if not all of
the changes in the gastric mucosal tissue may be as the result of
the antioxidative effects of NOSH-SUL.
Fig. 4. Anti-inﬂammatory properties of sulindac and NOSH-sulindac. Rat paw edema was induced by carrageenan injection as described in Section 2.9. SUL and NOSH-SUL
were both equally effective in reducing paw volume at all time points (panel A). Results are mean7SEM of 5 rats in each group, †Po0.05 vs vehicle treated rats at all time
points. SUL and NOSH-SUL also caused a signiﬁcant reduction in PGE2 levels in the paw exudate (panel B). Results are mean7SEM for 5 rats in each group, †Po0.01 vs
vehicle, *P o0.05 vs NOSH-SUL.
Fig. 5. Effect of sulindac and NOSH-sulindac on plasma TNF-α. At the end of the
gastrointestinal safety evaluations as described in Section 2.3, blood was drawn and
processed as described in Section 2.7 for determination of plasma TNF-α. SUL
caused a signiﬁcant rise in plasma TNF-α, however, this rise was signiﬁcantly less in
the NOSH-SUL-treated rats. Results are mean7SEM for 5 rats in each group,
*Po0.001 vs vehicle, §Po0.01 vs SUL.
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Sulindac is mainly used for treating inﬂammatory conditions.
We therefore wanted to compare the COX-dependent anti-in-
ﬂammatory activity of SUL to that of NOSH-SUL. For this, we used
the carrageenan-induced edema model [34]. After inducing in-
ﬂammation, animals receiving vehicle showed a fast time-depen-
dent increase in paw volume (ΔV¼0.5 mL) within 1 h, and gradual
increase to 1.3 mL over the course of the experiment (5 h)
(Fig. 4A). In contrast, animals receiving SUL or NOSH-SUL showed
a weak inﬂammatory response, ΔV¼0.2–0.3 mL by 1 h, which
peaked to ΔV¼0.40–0.45 mL at 2 h and then decreased over the
next 3 h (Fig. 4A). The anti-inﬂammatory effect registered in ani-
mals dosed with NOSH-SUL was comparable to those treated with
SUL. Prostaglandins (PGE2) are the main products of cycloox-
ygenase-mediated arachidonic acid metabolism [1]. Comparison of
PGE2 content of paw exudates showed a clear and signiﬁcant COX
inhibition by SUL and NOSH-SUL (Fig. 4B). PGE2 levels in control
vehicle-treated rats were 8574 pg mg1 and in the SUL and
NOSH-SUL-treated rats it went down to 971 pg mg1 and
2472 pg mg1, respectively. This is equivalent to reduction of 89%
and 72% by SUL and NOSH-SUL, respectively.
3.5. Plasma TNFα levels
We determined the inhibitory effect of SUL and NOSH-SUL on
the proinﬂammatory cytokine tumor necrosis factor-α in plasma
obtained from control and drug-treated animals at the end of the
gastrointestinal safety experiments, 6 h post-administration
(Section 2.3). Administration of SUL (200 mg/kg, 0.56 mmol/kg)
increased TNFα concentration by about 25-fold (9.570.3 control
and 23075 pg/mL SUL). However, this rise was considerably
lower in the NOSH-SUL-treated (476 mk/g, 0.56 mmol/kg) animals,
5073 pg/mL (Fig. 5).
3.6. Antipyretic activity
It is well known that NSAIDs exert a moderate antipyretic effect
when administered orally; although SUL is seldom used for that
purpose. Nevertheless for comparison considerations, we wanted
to determine the decrease in body temperature induced by NOSH-SUL compared to that obtained with SUL. Experimental drugs, SUL
and NOSH-SUL were administered orally at equimolar doses
(0.56 mmol/kg; 200 mg/kg and 467 mg/kg for SUL and NOSH-SUL,
respectively) 30 min before injecting the rats with LPS (50 μg/kg
ip). In this regard, control animals showed a time-dependent in-
crease in body temperature which leveled off between 3 and 4 h
Fig. 6. Sulindac and NOSH-sulindac reduce LPS-induced fever, raise the threshold for hyperalgesia, and show anti-platelet activity. Panel A: LPS (50 μg/kg, ip) was ad-
ministered to the rats one hour before administration of SUL or NOSH-SUL at equimolar doses (0.56 mmol/kg; 200 mg/kg and 467 mg/kg for SUL and NOSH-SUL, respec-
tively). Core body temperature was recorded at 30 min and thereafter hourly for 5 h. Results are mean7SEM for 5 rats in each group, *Po0.01 vs vehicle for both SUL and
NOSH-SUL from 1–5 h. Panel B: Mechanical pain threshold was increased in a time-dependent manner by SUL and NOSH-SUL. Results are mean7SEM for 5 rats in each
group. *Po0.05 vs vehicle for SUL and NOSH-SUL from 2–5 h.Panel C: SUL and NOSH-SUL were equally effective in inhibiting human platelet aggregation. Results are
mean7range for two individuals.
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screen (5 h). However, SUL and NOSH-SUL-treated animals
showed only about a half-degree increase in body temperature at
30 min after LPS injection, this increased to ΔT¼0.7 °C by 1 h
thereafter gradually decreased (Fig. 6A).
3.7. Carrageenan-induced mechanical hyperalgesia
This assay measures the ability of the test drugs to decreased
threshold to a painful stimuli produced by injection of carrageenan
onto the plantar surface of the right hind paw. The mechanical
pain threshold was increased upon time by administering of SUL
and NOSH-SUL (Fig. 6B). Pain threshold was markedly reduced
from 65 g to about 10 g in animals receiving vehicle (control
group), indicating a higher sensitivity to mechanical stimuli (non-
painful at normal conditions). Hyperalgesia was decreased in an-
imals receiving SUL and NOSH-SUL to the same extent, about 32 g
or 50% reduction compared to the initial response. Another NO-
and H2S-releasing NSAID, NOSH-aspirin (NBS 11–20) was recently
shown to have greater potency than aspirin in reducing in-
ﬂammatory pain in several clinically relevant models [39]. The
enhanced antinociceptive effect of NOSH-aspirin appeared to be
due to its ability to reduce the production of pronociceptive cy-
tokines such as IL-1β. NOSH-aspirin was also shown to reduce
hyperalgesia, caused by a directly acting hyperalgesic mediator in a
mechanism dependent on modulation of KATP channels. The latter
effect is presumably due to the released H2S as this gaso-
transmitter in known to affect [1,40].
3.8. Platelet anti-aggregatory activity
Sulindac is not used as an anti-aggregatory agent whereas as-
pirin is frequently employed for this purpose. This is primarily
because aspirin is an irreversible inhibitor of COX-1 whereas SUL is
not [24]. Nevertheless, since SUL does inhibit COX-1 we wanted to
compare the anti-aggregatory effects of NOSH-SUL to that of SUL
for complete characterization of these two compounds. We used
collagen-induced platelet aggregation of human platelet-rich
plasma (PRP) for the comparison. The results expressed as IC50s
are shown in Fig. 6C. Analysis of the data does not show any sta-
tistical differences between SUL and NOSH-SUL. It should be noted
that NOSH-SUL releases NO and H2S [29] both of which can have
independent anti-platelet properties [41–43].3.9. NOSH-SUL inhibits the growth of various human cancer cell
lines
We investigated the effects of SUL and NOSH-SUL on the
growth properties of 12 different cancer cell lines of six different
histological subtypes. The cell lines were that of colon (HT-29:
COX-1 and COX-2 positive, HCT 15: COX null, and SW480: COX-1
positive, low levels of endogenous COX-2), breast (MCF7: [ER(þ)],
MDA MB-231 and SKBR3: [ER()]); pancreatic (BxPC3: both COX-
1 and COX-2 positive, MIAPaCa-2: COX-null), lung (A549, H383),
prostate (LNCaP), and T-cell leukemia (Jurkat). NOSH-SUL was
extremely effective in inhibiting the growth of these cell lines
(Table 2). The IC50s for cell growth inhibition at 24 h for NOSH-SUL
ranged from 0.0970.01 to 0.3270.03 mM and that for SUL was
212737 to 935735 mM. The growth inhibition by NOSH-SUL
versus SUL was very high in the panel of cancer cell lines studied.
In a fold comparison study of the IC50 values (SUL/NOSH-SUL),
NOSH-SUL was at least 1000-fold to 9000-fold more potent than
SUL in various cell lies (Table 2). Such fold increases imply that the
NO and H2S-related structural modiﬁcations of the SUL molecule
imparts a differential enhancement in potency. Furthermore, our
data strongly suggests that this effect may be tissue-type in-
dependent since NOSH-SUL was effective against adenomatous,
epithelial, and lymphocytic cancer cell lines. Here we studied 12
cell lines originating from six different tissues, therefore, it may be
envisaged that our ﬁndings are part of a generalized effect. An
interesting aspect of growth inhibition also emerges with respect
to COX expression in the cell lines examined. NOSH-SUL showed
similar effects on two colon cancer cell lines, HT-29 (expresses
COX-1 and COX-2) and HCT 15 (no COX expression) [44] and on
two pancreatic cancer cell lines, BxPC-3 (expresses COXs) and MIA
PaCa-2 (no COX expression) [45] suggesting a COX-independent
effect.
Currently we cannot explain the underlying mechanism(s) for
the enhanced potency of NOSH-SUL observed in these studies. We
do not yet know anything about the kinetics of NO and H2S release
and their potential interactions. However, we do know that both
contribute towards the potency of the intact molecule. This is
based on our earlier observations where we showed that the
biological activity of aspirin plus SNAP (S-Nitroso-N-acetyl-peni-
cillamine, which releases NO) plus ADT-OH (5-(4-hydroxyphenyl)-
3H-1, 2-dithiole-3-thione, which releases H2S) was not the same
as the biological activity of the intact NOSH-aspirin molecule [46].
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K. Kashﬁ et al. / Redox Biology 6 (2015) 287–296294Thus the sum of parts did not equal the whole. The same was
observed for NOSH-naproxen [29]. So, we suspect the same will
hold true for NOSH-SUL. However, recent reports indicate that NO
can react with H2S to produce HSNO which is a highly reactive
intermediate [47,48]. Furthermore, NO and H2S signaling path-
ways appear to be intimately intertwined with mutual potentia-
tion of biological responses [49].
3.10. Effect of NOSH-SUL on cell growth kinetics
The effects of NOSH-SUL on cell proliferation, apoptosis, and
cell cycle transition, all of which affect cell growth were also ex-
amined in HT-29 colon cancer cells.
To determine the antiproliferative effects, HT-29 colon cancer
cells were treated with different concentration of NOSH-SUL for
24 h, followed by PCNA quantiﬁcation. The concentrations we used
were, 0.5 IC50 (50 nM), 1 IC50 (100 nM), and 2 IC50 (200 nM).
NOSH-SUL reduced proliferation in a dose-dependent manner, as
measured by the expression of PCNA, (Fig. 7A). Proliferation de-
creased to 7272%, to 5573% and to 3572% at 0.5 IC50, 1 IC50,
and 2 IC50, respectively.
To determine whether cells were undergoing apoptosis in ad-
dition to inhibition of cell proliferation, apoptotic population was
evaluated by Annexin V-FITC and propidium iodide staining, fol-
lowed by ﬂow cytometry. As shown in Fig. 7C, NOSH-SUL caused a
signiﬁcant increase in the number of cells undergoing apoptosis.
The percentage of apoptotic cells increased from 1872% at
0.5 IC50 to 4272% at 1 IC50, and 5873% at 2 IC50 compared
to control.
We also determined the effect of the NOSH-SUL on the dis-
tribution of cells in G0/G1, S, and G2/M phases of the cell cycle.
Cells were exposed to NOSH-SUL at concentrations of 0.5 IC50,
1 IC50, and 2 IC50 for 24 h, and analyzed for cell cycle phases by
ﬂow cytometry. DMSO-treated control cells proceeded through a
normal cell cycle. Increasing concentrations of NOSH-SUL were
associated with dose-dependent decreases in the percentage of
cells in G0/G1 and S phases, and a corresponding increase in the
percentages of cells in G2/M phase (Fig. 7B), suggesting a G2/M
phase cell cycle block. For example, at 1 IC50 the population cells
in G0/G1 phase of the cell cycle decreased from 40.6% to 31.4% and
the S phase was reduced from 32.7% to 14%, while the cells in G2/M
increased from 26.7% to 54.6%. This mode of cell cycle arrest has
been reported for the parent drug sulindac in SW480 human colon
cancer cells [50]. Thus, NOSH-SUL inhibits proliferation of HT-29
colon cancer cells by a combined induction of G2/M arrest and
apoptosis.Summary and future directions
In the present study, proof-of-concept animal studies demon-
strated that NOSH-sulindac is essentially devoid of any gastro-
intestinal side effects even though it reduces gastric tissue PGE2 le-
vels. The hybrid molecule retains all the positive pharmacological
attributes of its parent NSAID, sulindac. That is, it is a potent anti-
inﬂammatory and analgesic that has anti-pyretic and anti-platelet
activity. In addition to its GI safety, NOSH-sulindac might also prove
to have enhanced cardiovascular and renal safety proﬁles. This is
because NO and H2S have protective roles in the cardiovascular and
renal system [51–53]. NOSH-sulindac is also potentially useful as a
chemopreventive agent against many types of cancer. In this regard,
we are currently evaluating its utility in different animal models of
cancer such as the APCMin/þ mice. We are also deciphering its me-
chanism of action, focusing on molecular targets that are relevant to
inﬂammation and cancer and to possible interactions between NO
and H2S in producing a new signaling entity.
Fig. 7. Effect of NOSH-sulindac on colon cancer cell kinetics. NOSH-SUL inhibits proliferation by altering cell cycle progression and inducing apoptosis. HT-29 cells were
treated with vehicle, 0.5x IC50 (50 nM), 1 IC50 (100 nM) or 2 IC50 (200 nM) NOSH-SUL for 24 h and analyzed for (A) proliferation by PCNA antigen expression; (B) cell cycle
phases by PI staining and ﬂow cytometry; (C) apoptosis by Annexin V staining and ﬂow cytometry. In (A) and (C), results are mean7SEM for 3 different experiments
performed in duplicate, *Po0.05 compared to control. In (B), results are representative of two different experiments.
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